Cover Image

Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection

Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-C...

Full description

Saved in:
Bibliographic Details
Main Authors: Lorenza Romani (Author), Francesca Ippolita Calò Carducci (Author), Sara Chiurchiù (Author), Laura Cursi (Author), Maia De Luca (Author), Martina Di Giuseppe (Author), Andrzej Krzysztofiak (Author), Laura Lancella (Author), Paolo Palma (Author), Leonardo Vallesi (Author), Tiziana Corsetti (Author), Andrea Campana (Author), Emanuele Nicastri (Author), Paolo Rossi (Author), Stefania Bernardi (Author)
Format: Book
Published: MDPI AG, 2022-03-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-CoV-2 infection in children aged from 24 days to 18 years old.
Item Description:10.3390/children9030369
2227-9067

Similar Items